Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00574171 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma
A Phase 2 study of Metastatic Colorectal Cancer, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT00574171: Completed Phase 2 study of Metastatic Colorectal Cancer, sponsored by University of Wisconsin, Madison.
NCT00574171 is a Phase 2 study of Metastatic Colorectal Cancer that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 29 participants, below the 185-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00574171, a Phase 2 study of Metastatic Colorectal Cancer, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out how effective this combination is as a second line treatment for colorectal cancer that has spread from one part of the body to another (metastasized) or has not metastasized but is considered inoperable (unable to be removed by surgery). The side effects and survival experienced by subjects receiving these drugs will also be evaluated. This is a phase II research study.
Conditions Studied
Interventions
- DRUG Capecitabine
- DRUG lapatinib
Study Locations (1)
Wisconsin
- University of Wisconsin Paul P. Carbone Comprehensive Cancer Center - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2007-09 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
What the finished NCT00574171 record still lists
NCT00574171 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 185-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Metastatic Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Capecitabine is the first listed.
NCT00574171 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT00574171 about?
NCT00574171 is a clinical study titled "Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma". The purpose of this study is to find out how effective this combination is as a second line treatment for colorectal cancer that has spread from one part of the body to another (metastasized) or has not metastasized but is considered inoperable (unable to be removed by surgery). The side effects and...
What is the current status of trial NCT00574171?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2007-09. Estimated completion is 2009-08.
What conditions does trial NCT00574171 study?
This clinical trial studies the following conditions: Metastatic Colorectal Cancer.
What interventions are being tested in trial NCT00574171?
The interventions under investigation include: Capecitabine (DRUG), lapatinib (DRUG).
Who is sponsoring clinical trial NCT00574171?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00574171 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00574171's enrollment target sits among peer trials
29 35th of 45 higher than 10 of 45 other Metastatic Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
RECRUITING · Phase 2
-
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
RECRUITING · Phase 2
-
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
RECRUITING · Phase 2
-
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
RECRUITING · Phase 2
-
Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer
RECRUITING · Phase 2
-
Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia